150 related articles for article (PubMed ID: 38461088)
1. [Severe complications of systemic treatment in thoracic oncology].
Berghmans T; Brandão M; Ilzkovitz M; Meert AP
Rev Mal Respir; 2024 Apr; 41(4):317-324. PubMed ID: 38461088
[TBL] [Abstract][Full Text] [Related]
2. Antibody drug conjugates in thoracic malignancies.
Pacheco JM; Camidge DR
Lung Cancer; 2018 Oct; 124():260-269. PubMed ID: 30268471
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
[TBL] [Abstract][Full Text] [Related]
4. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
van Zandwijk N; Pavlakis N; Kao SC; Linton A; Boyer MJ; Clarke S; Huynh Y; Chrzanowska A; Fulham MJ; Bailey DL; Cooper WA; Kritharides L; Ridley L; Pattison ST; MacDiarmid J; Brahmbhatt H; Reid G
Lancet Oncol; 2017 Oct; 18(10):1386-1396. PubMed ID: 28870611
[TBL] [Abstract][Full Text] [Related]
5. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
7. [Malignant pleural mesothelioma: The role of surgery].
Fournel L; Janet-Vendroux A; Canny-Hamelin E; Mansuet-Lupo A; Guinet C; Bobbio A; Damotte D; Alifano M
Rev Pneumol Clin; 2018 Oct; 74(5):351-358. PubMed ID: 30316650
[TBL] [Abstract][Full Text] [Related]
8. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
Ceresoli GL; Aerts JG; Dziadziuszko R; Ramlau R; Cedres S; van Meerbeeck JP; Mencoboni M; Planchard D; Chella A; Crinò L; Krzakowski M; Rüssel J; Maconi A; Gianoncelli L; Grosso F
Lancet Oncol; 2019 Dec; 20(12):1702-1709. PubMed ID: 31628016
[TBL] [Abstract][Full Text] [Related]
9. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
Gregorc V; Gaafar RM; Favaretto A; Grossi F; Jassem J; Polychronis A; Bidoli P; Tiseo M; Shah R; Taylor P; Novello S; Muzio A; Bearz A; Greillier L; Fontana F; Salini G; Lambiase A; O'Brien M
Lancet Oncol; 2018 Jun; 19(6):799-811. PubMed ID: 29753703
[TBL] [Abstract][Full Text] [Related]
10. [Anti-tumor immunotherapy in malignant pleural mesothelioma].
Scherpereel A; Willemin MC; Wasielewski E; Dhalluin X
Rev Mal Respir; 2018 Apr; 35(4):465-476. PubMed ID: 29415822
[TBL] [Abstract][Full Text] [Related]
11. Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.
Remon J; Reguart N; Corral J; Lianes P
Cancer Treat Rev; 2015 Jan; 41(1):27-34. PubMed ID: 25467107
[TBL] [Abstract][Full Text] [Related]
12. Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial.
Hiltbrunner S; Britschgi C; Schuberth P; Bankel L; Nguyen-Kim TDL; Gulati P; Weder W; Opitz I; Lauk O; Caviezel C; Bachmann H; Tabor A; Schröder P; Knuth A; Münz C; Stahel R; Boyman O; Renner C; Petrausch U; Curioni-Fontecedro A
Ann Oncol; 2021 Jan; 32(1):120-121. PubMed ID: 33098996
[No Abstract] [Full Text] [Related]
13. Management of recurrence after initial surgery for malignant pleural mesothelioma: a mini-review.
Halezeroğlu S; Migliore M
Future Oncol; 2015; 11(24 Suppl):23-7. PubMed ID: 26638919
[TBL] [Abstract][Full Text] [Related]
14. Pleural mesothelioma: a snapshot of emerging drug targets and opportunities for non-surgical therapeutic advancement.
Assié JB; Jean D
Expert Opin Ther Targets; 2023; 27(11):1059-1069. PubMed ID: 37902459
[TBL] [Abstract][Full Text] [Related]
15. Multidisciplinary palliative treatment including isolated thoracic perfusion for progressive malignant pleural mesothelioma: a retrospective observational study.
Guadagni S; Masedu F; Zoras O; Zavattieri G; Aigner K; Guadagni V; Fumi L; Clementi M
J BUON; 2019; 24(3):1259-1267. PubMed ID: 31424688
[TBL] [Abstract][Full Text] [Related]
16. Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review.
Blomberg C; Nilsson J; Holgersson G; Edlund P; Bergqvist M; Adwall L; Ekman S; Brattström D; Bergström S
Anticancer Res; 2015 May; 35(5):2493-501. PubMed ID: 25964522
[TBL] [Abstract][Full Text] [Related]
17. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
Disselhorst MJ; Quispel-Janssen J; Lalezari F; Monkhorst K; de Vries JF; van der Noort V; Harms E; Burgers S; Baas P
Lancet Respir Med; 2019 Mar; 7(3):260-270. PubMed ID: 30660511
[TBL] [Abstract][Full Text] [Related]
18. Proton-coupled folate transporter as a biomarker of outcome to treatment for pleural mesothelioma.
Petri GL; Cascioferro S; Parrino B; Peters GJ; Diana P; Giovannetti E
Pharmacogenomics; 2018 Jul; 19(10):811-814. PubMed ID: 29916298
[No Abstract] [Full Text] [Related]
19. Targeted Approaches to Treatment of Pleural Mesothelioma: A Review.
Dagogo-Jack I
JCO Precis Oncol; 2023 Sep; 7():e2300344. PubMed ID: 37992257
[TBL] [Abstract][Full Text] [Related]
20. The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma.
Perera ND; Mansfield AS
Curr Oncol Rep; 2022 Nov; 24(11):1413-1423. PubMed ID: 35657483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
